Form 10-Q · Quarterly report
Charles River Laboratories 10-Q, filed Nov 4, 2026
- Filed
- CIK
- 0001100682
- Accession no.
- 0001100682-26-000157
Summary
Charles River Laboratories reported an improved client spending environment and a slight increase in Discovery and Safety Assessment backlog to $2.0 billion, and detailed a restructuring program expected to yield about $300 million in annualized cost savings by the end of 2026. The company also completed acquisitions, including an additional 79% of PathoQuest for $67.4 million and K.F. Cambodia Ltd assets for $507.3 million, and divested European Discovery Services to IQVIA for $126.4 million and CDMO and Cell Solutions to GI Partners.
Key points
- Charles River Laboratories reported an improved client spending environment, with Discovery and Safety Assessment backlog rising to $2.0 billion as of September 26, 2026 from $1.9 billion as of December 27, 2025.
- The company announced its Create the Future program in the third quarter of fiscal 2026, targeting approximately $300 million of cumulative annualized cost savings by the end of 2026 and more than $300 million of incremental savings between 2027 and 2030.
- It acquired an additional 79% equity interest in PathoQuest SAS for $67.4 million on April 17, 2026, and certain assets of K.F. Cambodia Ltd for a preliminary $507.3 million on January 14, 2026.
- It sold European Discovery Services to IQVIA for $126.4 million and CDMO and Cell Solutions to GI Partners, recognizing a $181.7 million pre-tax loss on the latter divestiture for the nine months ended September 26, 2026.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion Overview We are a leading, full service, non-clinical global drug development partner. For over 75 years, we have been in the business of providing the research models required in the research and development of new drugs, devices, and therapies. Over this time, we have built upon our original core competency of laboratory animal medicine and science (research model technologies) to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, that supports our clients from target identification through non-clinical development. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.